Pennington Biomedical researchers will present scientific findings and participate in expert discussions at ObesityWeek 2026, highlighting advances in obesity science and treatment. The institution will also contribute to educational and early-career programming.
Researchers at Hospital for Special Surgery have identified new methods to assess joint inflammation in rheumatoid arthritis, enabling more efficient treatment. By analyzing tissue samples and synovial fluid, they aim to improve treatment outcomes and reduce the risk of permanent damage.
A new study reveals that participating in cancer clinical trials can cause financial burdens, with median reimbursement of $2,128. The study suggests that reimbursement programs can improve equitable access to and retention in trials, making cancer clinical trials more accessible.
Dr. Joseph L. Wright has been selected as the 2027 David G. Nichols Health Equity Award recipient for his significant contributions to advancing child and adolescent health, well-being, and equity. The award recognizes his decades-long commitment to improving health equity and his transformative contributions to pediatric health.
The ISSCR has recognized five scientists with Poster Awards for their outstanding contributions to iPSC research, showcasing progress in the field. The award honorees are from Japan, Switzerland, and the US, and were recognized for their research in advancing the clinical applications of iPSC technology.
Dr. El-Khoueiry is an international leader in liver cancer treatment and clinical trials. He will advance USC Norris' mission to translate scientific discoveries into new cancer prevention, diagnosis, and treatment approaches.
The HuBMAP Data Portal offers a rich resource for deepening understanding of human health and disease, with 9,000 datasets from 500 donors. Researchers can explore and analyze complex relationships between trillions of cells using the portal's tools and visualization capabilities.
Dr. Petter Bjornstad will lead Pennington Biomedical Research Center in advancing research in metabolic disease, with a focus on improving the health and well-being of Louisiana residents. He brings exceptional expertise in diabetes and kidney disease, with a vision to translate world-class science into better health outcomes.
The ISSCR 2029 Annual Meeting will take place in Kyoto, Japan, showcasing discoveries across stem cell science and regenerative medicine. The event will foster international collaboration and accelerate progress in the field, with a focus on Japan's scientific leadership.
Researchers develop a new method using Raman spectroscopy to identify 20 SARS-CoV-2 variants and subvariants based on their molecular RNA architecture, which is distinct from their genetic composition. This approach has the potential to provide a rapid screening strategy for emerging viral variants.
The ISSCR has launched a new CDMO Directory to support stem cell research and clinical translation. The directory connects researchers with contract development and manufacturing organizations, providing a centralized resource for exploring manufacturing capabilities.
The ISSCR symposium in Kyoto, Japan celebrates 20 years of iPSC discovery, exploring fundamental discoveries, clinical translation, and emerging stem cell therapies. The event highlights key findings from recent research, including advances in iPSC biology, genetic stability, and disease modeling.
Researchers discovered a protein called Miro1 linked to insulin resistance in muscle, offering a potential new target for future diabetes treatments. Removing Miro1 restored muscle response to insulin in preclinical models, while exercise reduced protein levels in people with Type 2 diabetes.
DS1025, a CD25-directed antibody drug conjugate, targets immunosuppressive regulatory T cells in the tumor microenvironment, aiming to reduce a mechanism that can limit the body's immune response against cancer. The trial is an international effort to investigate DS1025 in patients with advanced solid tumors.
The International Society for Stem Cell Research (ISSCR) is now accepting abstract submissions and registrations for its 2027 Annual Meeting in San Francisco. The event will showcase groundbreaking discoveries and emerging technologies, including AI advancements and cell-based therapies.
Stem Cell Reports will be the official meeting journal for the Australasian Society for Stem Cell Research 2026 Annual Scientific Meeting. The journal will provide complimentary ISSCR memberships for selected researchers and host a co-branded webinar in 2027.
UChicago Medicine launches a groundbreaking clinical trial testing a new personalized cell therapy for advanced solid tumors, including ovarian cancer and melanoma. The treatment uses specially engineered T-cell receptors to detect hidden cancer proteins, expanding the number of cancers that can be targeted.
Researchers from Memorial Sloan Kettering Cancer Center have made several groundbreaking discoveries in the field of MSK research, including the role of immune cells in fueling triple-negative breast cancer and the development of a new strategy to combat leptomeningeal metastases. Additionally, the study found that trastuzumab deruxtec...
A new scale for reproductive aging in Chinese women has been developed based on ultra-sensitive AMH testing. The scale provides age-specific percentiles for AMH levels in women aged 35-55, enabling earlier identification of women at risk of low ovarian reserve and better management of perimenopausal symptoms.
BD2 is seeking additional clinical sites to join its Integrated Network, aiming to advance understanding of bipolar disorder. The network, spanning 11 institutions, combines longitudinal cohort study and learning health network to improve care outcomes.
The new CSO and EORTC recommendations aim to improve the reporting of quality of life in adjuvant cancer trials, enabling patients and clinicians to better understand the real-world impact of treatment. The recommendations focus on including validated patient-reported outcome measures and regular assessment throughout treatment.
A study of 349 participants found that high-competence physicians with warm communication styles reduced patients' worries and concerns over normal test results. Patients who saw high-competence physicians also reported lower likelihood of serious disease and less emotional concern.
The journal refines its evaluation criteria to emphasize translational impact, external validation, and actionable implementation in healthcare environments. Submissions will be evaluated based on real-world clinical applicability and systematic implementation of informatics solutions.
The journal welcomes leading researchers with expertise in hematopoietic and muscle stem cell biology, advancing understanding of stem cell research in health and disease. Drs. Bonnet and Relaix bring significant breadth of expertise and commitment to rigorous science, enhancing Stem Cell Reports' impact.
The AACR Cancer Progress Report 2026 highlights promising advances in cancer research, including FDA-approved new cancer drugs and the use of artificial intelligence. However, the report also underscores the need for sustained federal investment in cancer research to achieve a healthier future for all Americans.
UCLA researchers are launching a phase 1/2 clinical trial to evaluate the safety and efficacy of JAK inhibitors in preventing immune checkpoint inhibitor-induced type 1 diabetes. The trial aims to test whether these drugs can protect insulin-producing cells in patients who develop diabetes after cancer immunotherapy.
A new study suggests that most patients with localized appendix cancer can avoid chemotherapy after surgery, with fewer than 10% experiencing recurrence. The study identified specific tumor characteristics and genomic alterations that may help doctors predict which patients are at higher risk of recurrence.
The new imaging system allows scientists to capture high-resolution fluorescence images in real time under normal room lighting, giving them a more complete picture of biological changes. SphynxVision can capture multiple images per second and reveal remarkably small details, such as tiny blood vessels and clusters of cancer cells.
A new study suggests that children with cerebral palsy born very preterm may need closer nutritional and rehabilitation monitoring due to higher risks of undernutrition and functional impairments. The study found that gestational age should be considered when assessing nutrition and rehabilitation needs in children with cerebral palsy.
Researchers redefine neurodegenerative diseases as TDP-43 associated neurodegenerative disease (TAND), which shares biological roots with ALS, FTD, and LATE. This new framework could lead to more efficient drug development and improved clinical trials for rare conditions.
The Alliance for Clinical Trials in Oncology emphasizes the significance of clinical trials in advancing breast cancer treatments and early detection. The organization's work has led to a 44% decline in breast cancer mortality rates among women since 1989.
Dr. Lorenz Studer is known for his pioneering advances in stem cell biology, regenerative medicine, and the development of stem cell-based therapies for neurodegenerative disease.
Researchers developed a multiprotein approach to predict advanced tau pathology among amyloid-positive individuals, outperforming p-tau217 alone. This study suggests a scalable alternative to tau PET staging for clinical or research settings.
The partnership aims to increase enrollment in clinical trials, making research opportunities more accessible to patients. UCCCC and Lilly will work together to open studies faster and connect more patients with research opportunities.
Researchers analyzed patient data from five clinical trials to evaluate the impact of adding hormone therapy on postoperative radiation outcomes. While traditional pathological features can identify patients at higher risk of recurrence, they do not predict treatment benefit.
The Sylvester Comprehensive Cancer Center has been ranked the No. 1 cancer program in Florida and No. 23 nationally by US News & World Report. The center's multidisciplinary teams provide access to new therapies and innovative clinical trials, making it a destination for patients seeking advanced care.
Massey Comprehensive Cancer Center awarded $2.7M K12 grant to support multidisciplinary cancer research and mentor early-stage clinical investigators. The grant aims to optimize participation by high-risk individuals in Virginia.
The symposium marked the hospital's designation as a research-oriented hospital, featuring discussions on collaborative research ecosystems at various levels. Participants engaged in sessions covering future directions, strengthening regional and industry collaborations, and real-world cases of research commercialization.
Researchers at Terasaki Institute develop a wireless dual-compartment biochemical monitoring platform for real-time tracking of key biomarkers in perfusion fluid and bile during normothermic machine perfusion. The study shows improved interpretation of post-transplant outcomes with combined bile and perfusate data.
Researchers evaluate whether hypoimmune cell engineering can help transplanted insulin-producing cells survive without chronic immunosuppression. The study aims to develop a cell replacement approach that can function without chronic immunosuppression, providing a curative therapy for people with type 1 diabetes.
Researchers present new insights into an iPSC-derived neural progenitor cell therapy for chronic ischemic stroke, demonstrating safety and biological activity over extended follow-up. The findings have the potential to expand treatment options for patients living with chronic stroke disability.
The REGEN4HD study marks a significant milestone in the development of regenerative medicine approaches for Huntington's disease. The Phase 1b/2a trial enrolls early-stage symptomatic patients to evaluate safety and tolerability.
Researchers at ISSCR 2026 present interim clinical findings from the first Phase 1/2a trial of autologous iPSC-derived dopamine neuron precursor cells for Parkinson's disease. The approach uses each patient's own cells, and new genomic quality control methods ensure the manufactured cells are suitable for transplantation.
A Phase 1/2a clinical study demonstrates long-term survival of transplanted human neural progenitor cells in patients with retinitis pigmentosa, maintaining a favorable safety profile. Visual acuity remained stable, and imaging showed cells remaining present in the subretinal space for at least one year.
Early signs of clinical improvement have been observed in patients with treatment-resistant systemic sclerosis treated with investigational stem cell-derived CAR T-cell therapy, known as FT819. The therapy has demonstrated a reassuring safety profile and has the potential to expand access to patients who might otherwise face barriers t...
The STEM-PD trial demonstrated the safety and feasibility of stem cell-derived dopaminergic cell transplantation in patients with moderate to advanced Parkinson's disease. The findings mark an important step in evaluating this approach as a potential treatment strategy for neurodegenerative diseases.
The Robert A. Winn Excellence in Clinical Trials Award Program is training a new generation of physicians to solve healthcare's representation challenge through immersive education and mentorship. The program has grown rapidly, drawing hundreds of applicants annually from medical schools across the country.
Encellin reports non-fibrotic engraftment and host vascularization in Phase 1 trial participants, building on interim results. The findings support the company's approach to deliver cell therapy safely and durably without immunosuppression.
The International Society for Stem Cell Research convenes its 2026 Annual Meeting in Montréal, showcasing groundbreaking discoveries and emerging clinical advances. The meeting features nearly 1,300 scientific posters and presentations spanning every area of stem cell research.
The Damon Runyon Cancer Research Foundation is investing nearly $1.4 million to support three young physician-scientists with innovative ideas about cancer treatment. The awardees will receive funding and freedom to pursue research in the early stages of their careers, which has led to breakthroughs in immunotherapy and other areas.
A nationwide Japanese study of over 82,000 children found that exclusive breastfeeding for six months significantly reduces the risk of short sleep duration at one year of age. The study also suggests that breast milk's adaptability to infant needs and its melatonin content help regulate healthy sleep rhythms.
Researchers have identified IL1RAP as a key player in the tumor-driven inflammatory network that helps pancreatic cancer resist treatment. Blocking this receptor may help break down tumors and improve response to combination therapy.
The Robert A. Winn Clinical Investigator Pathway Program is launching its fifth cohort, welcoming 80 medical students from across the US and Puerto Rico for a six-week immersion in clinical research, community engagement, and improving clinical trial participation. Students will gain hands-on experience at leading institutions nationwide.
A recent study published in JAMA found that prone positioning in infants with moderate to severe bronchiolitis receiving high-flow nasal cannula support did not significantly reduce escalation of care. The study suggests that further research is warranted due to the wide confidence interval around the observed odds ratio.
Researchers developed LiON, a fluorescent reporter that visualizes biologically active iron and oxygen inside living cells. The tool revealed striking differences in iron and oxygen distribution across organs and cells, offering new opportunities to study diseases like cancer, liver disorders, and neurodegenerative conditions.
The FDA has accepted Genentech's supplemental Biologic License Application for atezolizumab, supported by phase III ATOMIC trial results. The trial showed a 50% reduction in cancer recurrence or death and 86.3% disease-free survival rate.
Eighty medical students from across the US and Puerto Rico are selected for a six-week summer experience to introduce them to clinical research early in their careers. The program aims to develop the next generation of clinical investigators equipped to engage communities and improve participation in clinical trials.
The ACT-CHIK project will conduct a Phase Ib/III clinical trial to evaluate the safety and immunogenicity of a measles-virus-based chikungunya vaccine in four African countries. The project also aims to strengthen Africa's vaccine ecosystem by transferring the vaccine manufacturing process to an African manufacturer.
Researchers will investigate the link between SYNGAP1 protein deficiency, cilia dysfunction, and clinical symptoms of SYNGAP1-Related Disorders. The study aims to inform rational drug design and provide new insights for targeted therapies.
A study published in JAMA Network Open found that maternal RSV vaccination reduces hospitalization risk in young infants by nearly 70%. The vaccine also showed effectiveness against severe lung infections caused by the virus.